E Fund Management (HK)’s ImmunityBio IBRX Stock Holding History

E Fund Management (HK)’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.5K	Buy	2,227 +565	+34%	+$4.28K	0.01%	321
2026 Q1	$12.7K	Buy	+1,662	New	+$11.4K	0.01%	304

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

E Fund Management (HK)'s IBRX Position: Q2 2026 in Review

E Fund Management (HK) increased its ImmunityBio (IBRX) stake by 34% in Q2 2026, buying an estimated $4.28K and bringing the position to 2,227 shares worth $19.5K. The position accounts for 0.01% of the portfolio, ranked #321.

E Fund Management (HK) first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

E Fund Management (HK) held 2,227 shares of ImmunityBio worth $19.5K as of Q2 2026.
E Fund Management (HK) bought 565 ImmunityBio shares in Q2 2026, an estimated $4.28K.
ImmunityBio made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #321 holding.
E Fund Management (HK) first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.